Cognition Therapeutics In... (CGTX)
0.46
0.00 (0.37%)
At close: Feb 28, 2025, 3:59 PM
0.45
-1.43%
Pre-market: Mar 03, 2025, 04:35 AM EST
No 1D chart data available
| Bid | 0.42 |
| Market Cap | 19.17M |
| Revenue (ttm) | 382.4K |
| Net Income (ttm) | -35.23M |
| EPS (ttm) | -0.96 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | -1.23 |
| Analyst | Buy |
| Ask | 0.45 |
| Volume | 770,528 |
| Avg. Volume (20D) | 7,604,948 |
| Open | 0.46 |
| Previous Close | 0.46 |
| Day's Range | 0.44 - 0.47 |
| 52-Week Range | 0.34 - 2.95 |
| Beta | 0.95 |
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinica...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol CGTX
Website https://www.cogrx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CGTX stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 1850.16% from the latest price.
Buy 83.33%
Hold 16.67%
Sell 0.00%
2 months ago
+9.31%
Cognition Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
2 months ago
+27.5%
Cognition Therapeutics shares are trading higher after the company announced topline results which met its primary endpoint of safety and tolerability from its exploratory Phase 2 SHIMMER study.
